Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

X
Trial Profile

A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Labuvirtide (Primary) ; Teropavimab (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Frontier Biotechnologies
  • Most Recent Events

    • 28 Sep 2021 Planned primary completion date changed from 1 Jul 2022 to 1 Nov 2022.
    • 28 Sep 2021 Planned initiation date (Estimated date of first participant enrolment) changed from 25 Dec 2020 to 30 Nov 2021.
    • 23 Nov 2020 Planned initiation date (Estimated date of first participant enrollement) changed from 25 Oct 2020 to 25 Dec 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top